The following primary objectives were selected: First, to evaluate the efficacy of NBO in reducing anemia in CRC patients undergoing chemotherapy by measuring markers of erythropoiesis, such as EPO levels, HIF-1α, and complete blood counts. This evidence concerns the gene EPO and anemia.